Pharmacokinetic Interaction Between the HCV Protease Inhibitor MK-5172 and Midazolam, Pitavastatin, and Atorvastatin in Healthy Volunteers

被引：0
|
作者：
Caro, Luzelena [1 ]
Talaty, Jennifer E. [1 ]
Guo, Zifang [2 ]
Reitmann, Christina [3 ]
Fraser, Iain P. [3 ]
Evers, Raymond [4 ]
Swearingen, Dennis [5 ]
Yeh, Wendy W. [3 ]
Butterton, Joan R. [3 ]
机构：
[1] Merck & Co Inc, Clin Drug Metab & Pharmacokinet, Whitehouse Stn, NJ USA
[2] Merck & Co Inc, Early Clin Dev Stat, Whitehouse Stn, NJ USA
[3] Merck & Co Inc, Clin Res, Whitehouse Stn, NJ USA
[4] Merck & Co Inc, Transporter In Vitro Technol, Whitehouse Stn, NJ USA
[5] Celerion, Tempe, AZ USA
来源：
HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
477
引用
收藏
页码：437A / 438A
页数：2
相关论文
共 50 条
  • [21] Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers
    Ma, Qing
    Forrest, Alan
    Rosenkranz, Susan L.
    Para, Michael E.
    Yarasheski, Kevin E.
    Reichman, Richard C.
    Morse, Gene D.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2008, 29 (02) : 91 - 101
  • [22] Pharmacokinetic Interaction Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Cyclosporine and Tacrolimus in Healthy Volunteers
    Hulskotte, Ellen
    Gupta, Samir
    Xuan, Fengjuan
    van Zutven, Marga
    O'Mara, Edward
    Feng, Hwa-Ping
    Wagner, John
    Butterton, Joan
    HEPATOLOGY, 2012, 56 (05) : 1622 - 1630
  • [23] THE PHARMACOKINETIC INTERACTION BETWEEN METHADONE AND THE INVESTIGATIONAL HCV PROTEASE INHIBITOR TELAPREVIR
    van Heeswijk, Rolf
    Vandevoorde, Ann
    Verboven, Peter
    Boogaerts, Griet
    De Paepe, Els
    van Solingen-Ristea, Rodica
    Beumont, Maria
    SWISS MEDICAL WEEKLY, 2011, 141 : 18S - 18S
  • [24] THE PHARMACOKINETIC INTERACTION BETWEEN METHADONE AND THE INVESTIGATIONAL HCV PROTEASE INHIBITOR TELAPREVIR
    van Heeswijk, R.
    Vandevoorde, A.
    Verboven, P.
    Boogaerts, G.
    De Paepe, E.
    van Solingen-Ristea, R.
    Garg, V.
    Beumont, M.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S491 - S492
  • [25] Pharmacokinetic evaluation of the interaction between the HCV protease inhibitor boceprevir and the HMG-CoA reductase inhibitors atorvastatin and pravastatin
    Hulskotte, Ellen G.
    Gupta, Samir
    Xuan, Fengjuan
    Van Zutven, Marga
    O'Mara, Edward
    Wagner, John A.
    Butterton, Joan R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 170 - 170
  • [26] Insight into the mechanisms of resistance-associated variants of HCV NS3 protease binding to MK-5172: A computational study
    Guo, Zhuyan
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [27] Evaluation of the Pharmacokinetic Drug-Drug Interaction between Micronized Fenofibrate and Pitavastatin in Healthy Volunteers
    Lee, Hae Won
    Kang, Woo Youl
    Jung, Wookjae
    Gwon, Mi-Ri
    Cho, Kyunghee
    Yang, Dong Heon
    Yoon, Young-Ran
    Seong, Sook Jin
    PHARMACEUTICS, 2020, 12 (09) : 1 - 10
  • [28] PHARMACOKINETIC INTERACTIONS BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND SIROLIMUS IN HEALTHY SUBJECTS
    Hulskotte, E. G.
    Feng, H. -P.
    Xuan, F.
    Lin, W.
    Zhu, Y.
    Rasmusen, S.
    Butterton, J. R.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S190 - S190
  • [29] The Combination of MK-5172, an NS3 inhibitor, and MK-8408, an NS5A Inhibitor, Presents a High Genetic Barrier to Resistance in HCV Genotypes
    Lahser, Frederick
    Bystol, Karin
    Curry, Stephanie
    McMonagle, Patricia
    Liu, Rong
    Xia, Ellen
    Chase, Robert
    Black, Stuart
    Ferrari, Eric B.
    Tong, Ling
    Yu, Wensheng
    Kozlowski, Joseph
    Asante-Appiah, Ernest
    HEPATOLOGY, 2014, 60 : 1168A - 1168A
  • [30] Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers
    Kim, Jae Hoon
    Sunwoo, Jung
    Song, Ji Hye
    Seo, Yu-Bin
    Jung, Won Tae
    Nam, Kyu-Yeol
    Kim, YeSeul
    Lee, Hye Jung
    Moon, JungHa
    Jung, Jin-Gyu
    Hong, Jang Hee
    PHARMACEUTICALS, 2022, 15 (08)
12345